Brasília – The Supreme Federal Court (STF) will hold two public hearings, convened by Justice Gilmar Mendes, to monitor the implementation of rulings related to Theme 1,234, which concerns the supply of medicines registered by Anvisa but not standardized within the Unified Health System (SUS).

The first hearing, set for November 10, 2025, will discuss drug pricing procedures managed by Anvisa and the Drug Market Regulation Chamber (CMED). Among the invited speakers are Ludhmila Abrahão Hajjar, Congressman Dr. Luizinho, Denizar Vianna, Marcos Pinto (Ministry of Finance), Daniel Wei Liang Wang, Anvisa President Leandro Safatle, CMED Executive Secretary Mateus Amâncio, and Fernanda De Negri (Ministry of Health).

The second hearing, scheduled for December 1, 2025, will address the development of Brazil’s national health platform, aimed at integrating data on medicine dispensing across the SUS network. Both sessions will take place at the STF’s Second Chamber and be open to the public in person and online.

Justice Mendes emphasized that STF oversight will focus on two key fronts: (1) the linkage between drug registration and pricing analysis by CMED and Conitec, particularly for innovative and rare-disease therapies; and (2) the creation of the national dispensing platform, to be developed by the TRF-4 IT team and later managed by the CNJ. The rapporteur also noted partial implementation by Anvisa, which introduced RDC 948/2024, requiring companies to request pricing within 60 days of registration for priority or rare-disease drugs.

Source: NK Consultores